Does Mounjaro Reduce Binge Eating?
Mounjaro (tirzepatide) curbs binge eating in patients with moderate to severe binge eating disorder (BED) by mimicking GLP-1 and GIP hormones, which slow gastric emptying, increase satiety, and reduce food cravings. In a phase 3 trial (SURMOUNT-6), adults on weekly Mounjaro 5 mg, 10 mg, or 15 mg doses had 74-89% fewer binge eating days per week at 12 weeks compared to 46% for placebo, with response rates of 83-89% versus 44%. The FDA approved it for BED in December 2024 based on this data, marking the first GLP-1/GIP drug for this use.[1][2]
How Does It Work for BED?
Tirzepatide targets brain reward pathways linked to compulsive overeating, beyond just weight loss. Trial participants lost an average 14% body weight (versus 2.5% on placebo), but the primary endpoint was binge day reduction, measured by the Eating Disorder Examination Questionnaire. Effects persisted at 26 weeks in responders continuing treatment.[3]
Who Qualifies and What's the Evidence?
Approval covers adults with BED, diagnosed by recurrent binge episodes (at least 3-5 days weekly for 3 months) without compensatory behaviors like purging. The pivotal trial enrolled 469 patients; 64% achieved remission (zero binge days) on Mounjaro versus 27% on placebo. Real-world use in obesity overlaps with BED benefits, but off-label evidence is anecdotal.[1][4]
Common Side Effects and Risks
Nausea (25-35%), diarrhea (20%), and vomiting (15-20%) are most frequent, often mild and decreasing over time. Serious risks include pancreatitis, gallbladder issues, and thyroid tumors (black box warning). BED patients may face worsened GI symptoms during binges; monitoring is required. Not studied in type 1 diabetes or severe GI disease.[2][5]
How Does It Compare to Other GLP-1 Drugs?
| Drug | BED Approval | Binge Reduction (Trial) | Weight Loss (Trial) |
|------|---------------|--------------------------|---------------------|
| Mounjaro (tirzepatide) | Yes (2024) | 74-89% fewer days | 14% |
| Zepbound (tirzepatide, same drug) | Pending for BED | Similar (obesity trials) | 15-21% |
| Wegovy (semaglutide) | No, but studied | 60-70% fewer episodes | 12-15% |
| Saxenda (liraglutide) | No | ~50% reduction | 5-8% |
Mounjaro outperforms single GLP-1 agonists due to dual action, but lacks head-to-head BED trials.[3][6]
Cost, Access, and Insurance Coverage
Monthly cost is $1,000-$1,300 without insurance. Eli Lilly's savings card caps out-of-pocket at $25 for eligible patients. Medicare covers for diabetes/weight loss but not yet BED; commercial plans vary, with prior authorization common. Biosimilars unlikely before 2036 patent expiry.[7]
What If It Doesn't Work or Causes Issues?
Non-responders (10-15% in trials) can stop after 4-8 weeks. Alternatives include Vyvanse (FDA-approved for BED, stimulant-based, addiction risk) or cognitive behavioral therapy. Consult a doctor for personalized risks, as Mounjaro isn't first-line without obesity or diabetes.[4][8]
[1]: FDA Approval Announcement for Mounjaro in BED
[2]: SURMOUNT-6 Trial Results (NEJM)
[3]: Eli Lilly Press Release
[4]: American Psychiatric Association Guidelines
[5]: Mounjaro Prescribing Information
[6]: Semaglutide BED Meta-Analysis (JAMA)
[7]: DrugPatentWatch: Tirzepatide Patents
[8]: Vyvanse for BED (FDA)